For investors in Singapore
SUSTAINABLE INVESTMENT SOLUTIONS
Invest with Purpose for a Better Tomorrow
We believe in investing for the future, not borrowing from it.
Corporate Debt Index
The Corporate Debt Index is a study into trends in company indebtedness around the world.
Quarterly insight from our equity teams to help clients navigate the markets and opportunities ahead.
Fixed Income Perspectives
Quarterly insight from our fixed income teams to help clients navigate the markets and opportunities ahead.
Sovereign Debt Index
The Sovereign Debt Index is a long-term study into trends in government indebtedness around the world, the investment opportunities this provides and the risks it presents.
Subscribe for relevant insights delivered straight to your inbox
A discussion of the potential benefits that can be realized in returns, risk management and the ability to influence companies’ sustainability practices through active engagement.
The current semiconductor shortage may be more pervasive and longer-lasting than many expect.
The sharp sell-off in government bond yields in the last few weeks is testing the patience of central banks and bond markets are reacting to the hawkish messages. Portfolio Manager Andrew Mulliner explains.
Defining impact investing, why it is important, and why we are passionate about it.
Carbon reduction represents a significant source of sustained growth for many natural resource companies.
The imminent arrival of tapering by the Federal Reserve amplifies challenges facing bond investors.
Given fluctuating markets, it may be prudent to sharpen the focus on sources of risk and return within one’s portfolio.
After months in which excess liquidity has fueled strong returns in equities and fixed income, investors may need alternatives.
We believe active managers are in a position to drive positive change amid the shift to sustainability.
Natural resources companies will play a key role in the transition to a low-carbon economy.
The highly infectious variant of COVID-19 has led to rising case numbers, but we explain why a return to normalcy is still within striking distance.
The sector is experiencing its worst period of relative underperformance on record. But some of history’s biggest biotech pains have been followed by memorable gains.